Kereiakes DJ, Ellis SG, Metzger DC, et al. - Given that bioresorbable vascular scaffold (BVS) vs cobalt chromium everolimus-eluting stents (EES) provided non-inferior rates of target lesion failure (cardiac death, target vessel myocardial infarction [TVMI] or ischemia-driven target lesion revascularization) at 1 year in the ABSORB III trial, and increased adverse event rates (particularly TVMI and scaffold thrombosis) after BVS was reported between 1 year and 3 years, and cumulative to 3 years, therefore, researchers evaluated clinical results following BVS through 5 years, including beyond the 3-year time point of complete scaffold resorption. A rise in the cumulative 5-year adverse event rates was documented after BVS vs EES in the ABSORB III trial. However, the period of excess risk for BVS ceased at 3 years coincident with complete scaffold resorption.